Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Central nervous system depression

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    64 result(s) found for: Central nervous system depression. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2007-000905-31 Sponsor Protocol Number: 11492C Start Date*: 2007-05-03
    Sponsor Name:H. Lundbeck A/S
    Full Title: A long term open label, flexiable dose, extension study evaluationg the safety and tolerability of Lu AA21004 in patients with Major Depressive Disorder
    Medical condition: Indication: Major Depressive Disorder according to the DSM-IV-TR
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009710 CNS depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) CZ (Completed) SE (Completed) IT (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2013-002654-75 Sponsor Protocol Number: EVP-6124-026 Start Date*: 2015-08-04
    Sponsor Name:Forum Pharmaceuticals Inc.
    Full Title: A 26-Week Extension Study of the Safety and Clinical Effects of EVP-6124 in Subjects with Alzheimer’s Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
    Medical condition: Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    18.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) NL (Completed) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002942-35 Sponsor Protocol Number: CTU/2017/285 Start Date*: 2019-10-31
    Sponsor Name:University College London Comprehensive Clinical Trials Unit
    Full Title: A Randomised Controlled Trial of Escitalopram and Nortriptyline compared with placebo and standard psychological care for depression in Parkinson’s Disease
    Medical condition: Depression in Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10012378 Depression PT
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-001656-35 Sponsor Protocol Number: 109MS408 Start Date*: 2014-04-07
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Open-Label Study Evaluating the Effectiveness of Oral Tecfidera™ (Dimethyl Fumarate) on MS Disease Activity and Patient-Reported Outcomes in Subjects with Relapsing-Remitting Multipl...
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    19.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed) BE (Completed) PT (Completed) IT (Completed) CZ (Completed) SK (Completed) ES (Completed) SI (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-001025-53 Sponsor Protocol Number: 109MS405 Start Date*: 2015-03-05
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Open-Label Study to Evaluate Fatigue in Subjects With Relapsing Remitting Multiple Sclerosis During Treatment With Tecfidera® (Dimethyl Fumarate) Gastro-Resistant Hard Capsule
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    17.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-001520-37 Sponsor Protocol Number: KETECT Start Date*: 2014-02-14
    Sponsor Name:Skåne University Hospital, Malmö
    Full Title: Ketamine as an alternative to electroconvulsive therapy for treatment of major depressive disorder
    Medical condition: Major depression disorder
    Disease: Version SOC Term Classification Code Term Level
    18.0 10037175 - Psychiatric disorders 10019063 Hallucination PT
    18.0 10015919 - Eye disorders 10013036 Diplopia PT
    18.0 100000004863 10061243 Post procedural nausea LLT
    18.0 10029205 - Nervous system disorders 10047343 Vertigo CNS origin PT
    18.0 10037175 - Psychiatric disorders 10015533 Euphoria LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003771-18 Sponsor Protocol Number: GWSP08258 Start Date*: 2013-08-06
    Sponsor Name:GW Pharma Ltd.
    Full Title: The efficacy, safety and tolerability of Sativex as an adjunctive treatment to existing anti-spasticity medications in children aged 8 to 18 years with spasticity due to cerebral palsy or traumatic...
    Medical condition: Spasticity due to cerebral palsy (CP) or traumatic central nervous system injury.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10028335 Muscle spasticity PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2020-005162-33 Sponsor Protocol Number: RF-2018-12365308 Start Date*: 2022-11-08
    Sponsor Name:IRCCS CENTRO SAN GIOVANNI DI DIO - FATEBENEFRATELLI AFFERENTE ALLA PROVINCIA LOMBARDO VENETA ORDINE OSPEDALIERO DI SAN G
    Full Title: Targeting inflammation in depression using minocycline: a patient stratification approach using peripheral inflammatory biomarkers, PET and MRI
    Medical condition: depressed patients with high levels of inflammation (crp>2 mg/l) and non responder to at least two different antidepressants
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002254-70 Sponsor Protocol Number: 6002-014 Start Date*: 2014-02-28
    Sponsor Name:Kyowa Kirin Pharmaceutical Development, Inc.
    Full Title: A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaulate the Efficacy of Oral Istradefylline 20 and 40 mg/day as Treatment for Subjects with Moderate to Sever...
    Medical condition: Moderate to severe Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    19.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-018878-21 Sponsor Protocol Number: SSAT036 Start Date*: 2010-08-16
    Sponsor Name:St Stephen's AIDS Trust
    Full Title: A phase III, open-label, single centre, single-arm, pilot study to assess the feasibility of switching, individuals receiving efavirenz with continuing Central Nervous System (CNS) toxicity, to ral...
    Medical condition: HIV
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002284-15 Sponsor Protocol Number: SSAT058 Start Date*: 2015-04-01
    Sponsor Name:St Stephen's AIDS Trust
    Full Title: SSAT058: A phase IV, open-label, multi centre pilot study to assess changes in cerebral function parameters in patients without perceived Central Nervous System (CNS) symptoms when switched from te...
    Medical condition: HIV
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-001476-11 Sponsor Protocol Number: AL002-2 Start Date*: 2020-11-12
    Sponsor Name:Alector Inc.
    Full Title: A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AL002 IN PARTICIPANTS WITH EARLY ALZHEIMER’S DISEASE
    Medical condition: Early Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) PL (Completed) DE (Completed) IT (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000559-26 Sponsor Protocol Number: PRAG-MS Start Date*: 2017-09-14
    Sponsor Name:FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
    Full Title: A multicentric randomized PRAGmatic trial to compare the effectiveness of fingolimod versus dimethyl-fumarate on patient overall disease experience in relapsing remitting Multiple Sclerosis: novel...
    Medical condition: relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000520-14 Sponsor Protocol Number: NL46653 Start Date*: 2014-07-31
    Sponsor Name:University Medical Center Utrecht
    Full Title: Prednisolone addition for atients with recent onset psychotic disorder: the role of immune-modulating strategies in the treatment of psychosis.
    Medical condition: Schizophrenia, schizophreniphorm disorder, schizoaffective disorder, psychosis NOS.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002558-64 Sponsor Protocol Number: CP1/2013 Start Date*: 2013-12-18
    Sponsor Name:dipartimento di neurologia e psichiatria
    Full Title: A randomised, placebo-controlled trial investigating the role of fampiridina in improving cognitive function of patients with multiple sclerosis.
    Medical condition: MULTIPLE SCLEROSIS
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-024265-40 Sponsor Protocol Number: KETA-FAN Start Date*: 2011-10-27
    Sponsor Name:HOSPITAL UNIVERSITARI DE BELLVITGE
    Full Title: Perineural vs systemic N-methyl-D-aspartate (NMDA) receptors antagonism with ketamine as a reverser of peripheral and central sensitization in phantom limb pain
    Medical condition: Phantom limb pain
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10034804 Phantom limb pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002683-24 Sponsor Protocol Number: CP-NU100-01.00 Start Date*: 2012-01-30
    Sponsor Name:Nuron Biotech, Inc.
    Full Title: A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the safety and efficacy of NU100 in patients with relapsing forms of multiple sclerosis
    Medical condition: Relapsing forms of multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) HU (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-002205-22 Sponsor Protocol Number: SSAT047 Start Date*: 2012-10-02
    Sponsor Name:St Stephen's AIDS Trust
    Full Title: A phase III, open-label, multi centre pilot study to assess the feasibility of switching, individuals receiving Atripla or Kivexa plus Efavarinz with continuing Central Nervous System (CNS) toxicit...
    Medical condition: HIV
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-001523-24 Sponsor Protocol Number: 14744001 Start Date*: 2016-03-25
    Sponsor Name:UHToulouse
    Full Title: Evaluation of the analgesic effects of prolonged-release oxycodone and of L-Dopa, versus placebo, on central neuropathic pain in Parkinson's disease : OXYDOPA trial
    Medical condition: Central neuropathic pain in Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-000271-39 Sponsor Protocol Number: 2022-01 Start Date*: 2022-09-02
    Sponsor Name:Adeptio Pharmaceuticals Ltd
    Full Title: Single-arm, open-label dose titration phase 2 clinical trial of (+)-α-DHTBZ for the treatment of tardive dyskinesia (TD)
    Medical condition: Tardive dyskinesia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10043118 Tardive dyskinesia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 16 15:24:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA